Croissy-Beaubourg, May 14, 2019, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialized in in vitro diagnostics and theranostics, is today announcing plans to accelerate its development in the United States, the world’s largest market for in vitro diagnostics and biotherapies.

In this context, Theradiag signed a new contract with HalioDx, a French expert specialized in the innovative diagnosis of digestive system diseases, with a base in the United States through its own CLIA laboratory.